Helical Secures Funding to Build Reproducible AI Discovery Platform

/ AI, Application Development, Machine Learning

The News

Helical raised $10M in seed funding to expand its virtual AI lab platform, designed to turn biological foundation models into reproducible, decision-ready workflows for pharmaceutical discovery. 

Analysis

AI in Pharma Moves From Models to Reproducible Systems

The application development landscape in life sciences is shifting from experimentation with AI models to building reproducible, production-grade systems that can support real scientific decisions. Helical’s virtual AI lab reflects this transition by focusing not just on model outputs, but on the workflows and systems required to operationalize them.

Efficiently Connected research shows that 74.3% of organizations rank AI/ML as a top investment priority, yet many initiatives stall before reaching production. In pharma, this gap is even more pronounced, where scientific rigor, reproducibility, and auditability are critical.

For developers, this signals a move toward building AI-powered platforms that integrate models, data, and workflows into cohesive systems rather than isolated experimentation environments.

Application Layers Emerge as the Missing Link in AI Adoption

Helical’s positioning as an “application layer” highlights a broader trend across the application development market: the realization that models alone are not sufficient to deliver business outcomes. Instead, organizations are investing in platforms that orchestrate models, manage data, and provide interfaces for domain experts.

In pharma, this challenge is amplified by the disconnect between ML engineers and scientists. Helical’s dual-surface approach (i.e., Virtual Lab for scientists and Model Factory for engineers) aims to address this gap by enabling collaboration within a shared system.

This aligns with a growing industry pattern where platforms are designed to bridge domain expertise and technical capabilities, which would enable more seamless workflows and reduce the friction between experimentation and production.

Market Challenges and Insights in AI-Driven Drug Discovery

The pharmaceutical industry faces structural challenges that make AI adoption both necessary and complex. Despite significant R&D investment, discovery timelines remain long, costs are high, and success rates are low. AI offers the potential to accelerate these processes, but operationalizing that potential remains difficult.

One of the key challenges is reproducibility. Many AI-driven experiments are conducted in isolated environments, making it difficult to validate results or transfer insights across programs. This creates inefficiencies and limits the scalability of AI initiatives.

Another challenge is the integration of diverse data sources and models. Biological systems are inherently complex, and ensuring that AI outputs are grounded in meaningful, interpretable data is critical for decision-making. Without this, AI risks being perceived as a black-box tool rather than a reliable component of the discovery process.

In-Silico Workflows and AI Orchestration Redefine Development Models

Helical’s focus on in-silico discovery workflows represents a broader shift toward computational-first approaches in application development for life sciences. By enabling scientists to test hypotheses at the speed of inference, these platforms may significantly reduce reliance on physical experimentation.

Efficiently Connected research indicates that over 70% of organizations are prioritizing data-driven and AI-enhanced application capabilities, which increasingly include simulation, modeling, and predictive analytics. In pharma, this translates into platforms that can orchestrate complex workflows across models, datasets, and user roles.

For developers, this evolution introduces new requirements around workflow orchestration, reproducibility, and explainability. Building systems that can support these capabilities will be critical to enabling AI-driven innovation in highly regulated and scientifically rigorous environments.

Looking Ahead

The pharmaceutical application development market is moving toward integrated AI platforms that combine modeling, data, and workflow orchestration into unified systems. As organizations seek to improve R&D throughput and reduce costs, the ability to operationalize AI at scale will become a key differentiator.

Helical’s approach highlights the importance of building application layers that make AI outputs reproducible and actionable. As this model gains traction, developers can expect increased demand for platforms that bridge the gap between experimentation and production, enabling more reliable and scalable AI-driven discovery processes across the life sciences industry.

Author

  • With over 15 years of hands-on experience in operations roles across legal, financial, and technology sectors, Sam Weston brings deep expertise in the systems that power modern enterprises such as ERP, CRM, HCM, CX, and beyond. Her career has spanned the full spectrum of enterprise applications, from optimizing business processes and managing platforms to leading digital transformation initiatives.

    Sam has transitioned her expertise into the analyst arena, focusing on enterprise applications and the evolving role they play in business productivity and transformation. She provides independent insights that bridge technology capabilities with business outcomes, helping organizations and vendors alike navigate a changing enterprise software landscape.

    View all posts